ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Washington, DC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Neoplasm Metastasis
Cognitive Dysfunction

Multiple Sclerosis (MS) trials near Washington, DC, USA:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Active, not recruiting
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Washington, District of Columbia, United States and 56 other locations

Locations recently updated

will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...

Active, not recruiting
Multiple Sclerosis (MS)
Drug: Ocrelizumab
Drug: rHuPH20

Phase 1

Roche
Roche

Washington, District of Columbia, United States and 19 other locations

sclerosis (MS) and have recently been advised to start the medication ublituximab (Briumvi) or are currently on another medication ...

Begins enrollment in 2 months
Multiple Sclerosis (MS) - Relapsing-remitting
Other: Other disease modifying therapies
Drug: Ublituximab
University of Maryland Baltimore (UMB)
University of Maryland Baltimore (UMB)

Baltimore, Maryland, United States

Many patients with multiple sclerosis (MS) experience "relapses" of disease activity during which they have increased numb...

Active, not recruiting
Multiple Sclerosis
Other: Communication with the clinic
Johns Hopkins University
Johns Hopkins University

Baltimore, Maryland, United States

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Phase 2

Biogen
Biogen

Lutherville, Maryland, United States and 76 other locations

Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatmen...

Enrolling
Multiple Sclerosis
Multiple Sclerosis Fatigue
Drug: Placebo
Drug: Solriamfetol

Phase 2

Johns Hopkins University
Johns Hopkins University

Baltimore, Maryland, United States

of nasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS).The primary objectives that this stu...

Enrolling
Secondary Progressive Multiple Sclerosis
Drug: Foralumab
Other: Placebo

Phase 2

Tiziana Life Sciences

Baltimore, Maryland, United States and 4 other locations

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Drug: Disease modifying treatment (DMT)
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Lutherville, Maryland, United States and 40 other locations

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: Ocrelizumab
Drug: Fingolimod

Phase 3

Roche
Roche

Washington, District of Columbia, United States and 106 other locations

This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...

Enrolling
Relapsing Multiple Sclerosis
Drug: Placebo
Drug: Obexelimab

Phase 2

Zenas BioPharma

Vienna, Virginia, United States and 48 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems